Overview

* Aurora Cannabis fiscal Q1 2026 rev rises 17%, driven by medical cannabis growth

* Adjusted EBITDA for fiscal Q1 grows 209%, reflecting strong operational performance

* Co maintains strong balance sheet with $186 mln cash and debt-free cannabis business

Outlook

* Aurora expects Q2 2026 net revenue to grow year-over-year

* Company anticipates 8%-12% growth in Global Medical Cannabis segment

* Aurora sees adjusted gross margins rising by 250-475 basis points

* Company expects significant cash outflows to impact Q2 2026 free cash flow

Result Drivers

* MEDICAL CANNABIS - 37% increase in global medical cannabis revenue driven by higher sales in Australia, Germany, Poland, and the UK

* INTERNATIONAL GROWTH - 85% growth in international medical cannabis revenue, now accounting for 57% of global medical cannabis net revenue

* PLANT PROPAGATION - 4% revenue increase due to organic growth and expanded product offerings, despite inventory write-offs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 C$64.80

Revenue mln

Q1 C$10.80

Adjusted mln

EBITDA

Q1 52.0%

Adjusted

Gross

Margin

Q1 C$49 mln

Adjusted

Gross

Profit

Q1 Net -C$19.40

Income mln

from

Cont Ops

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)